MET/HGF pathway activation as a paradigm of resistance to targeted therapies.

ABSTRACT: Resistance to targeted therapeutics is a key issue limiting the long-term utility of these medications in the management of molecularly selected subsets of cancer patients, including patients with non-small cell lung cancer harboring oncogenic alterations affecting EGFR, ALK and other genes. Bypass resistance mediated by activation of MET kinase has emerged as a frequent, validated and pivotal resistance mechanism in multiple types of cancers. Biochemical understanding is accumulating to explain the unique role of MET in such bypass pathways, providing alternate downstream activation opportunities and intricate interactions during epithelial-mesenchymal transitions. Multiple diagnostic testing platforms have become available for selecting appropriate patients for MET targetin

SUBMITTER: Ko B 

PROVIDER: S-EPMC5253284 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature